Neurocrine Biosciences Inc (NBIX)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current NBIX market cap is 14.03B. The company's latest EPS is USD 2.4662 and P/E is 56.18.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 498.8M | 515.2M | 515.3M | 590.2M | 622.1M |
| Operating Income | 141.2M | 150.3M | 99.3M | 145.4M | 183.8M |
| Net Income | 83.1M | 147.7M | 43.4M | 65M | 129.8M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 788.09M | 1.05B | 1.13B | 1.49B | 1.89B |
| Operating Income | 72.28M | 163M | 102.5M | 249M | 250.9M |
| Net Income | 37.01M | 407.3M | 89.6M | 154.5M | 249.7M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.85B | 3.25B | 3.47B | 3.31B | 3.54B |
| Total Liabilities | 846.1M | 1.02B | 1.09B | 795.8M | 816.1M |
| Total Equity | 2B | 2.23B | 2.39B | 2.51B | 2.72B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B |
| Total Liabilities | 669.12M | 608.5M | 698.5M | 660.9M | 1.02B |
| Total Equity | 636.92M | 1.13B | 1.37B | 1.71B | 2.23B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 266.4M | 389.9M | 130.3M | 194.9M | 352.9M |
| Investing | -265.3M | -467.1M | -55M | -83.2M | -58.5M |
| Financing | 29.9M | 65.3M | 69.9M | -223.1M | -196.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 152.05M | 228.5M | 256.5M | 339.4M | 389.9M |
| Investing | -211.07M | 4.1M | -130.2M | -177.1M | -467.1M |
| Financing | 27.31M | -157.8M | 27.4M | -234.3M | 65.3M |
| Market Cap | 14.03B |
| Price to Earnings Ratio | 56.18 |
| Price to Sales Ratio | 7.43 |
| Price to Cash Ratio | 55.86 |
| Price to Book Ratio | 6.28 |
| Dividend Yield | - |
| Shares Outstanding | 101.25M |
| Average Volume (1 week) | 1.22M |
| Average Volume (1 Month) | 975.8k |
| 52 Week Change | 7.58% |
| 52 Week High | 157.9799 |
| 52 Week Low | 110.95 |
| Spread (Intraday) | 0.13 (0.09%) |
| Company Name | Neurocrine Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.neurocrine.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
